Many men with erectile dysfunction (ED) have hypertension as a comorbid condition. Recent guidelines recommend thiazide diuretics as first-line therapy for hypertension. We analyzed data from 14 randomized, double-blind, placebo-controlled trials (N ¼ 2501) to evaluate the efficacy of tadalafil 20 mg for the treatment of ED in men on thiazides. Of the 2501 patients, 163 were on concomitant thiazides (116 tadalafil/47 placebo) and 159 (98%) were reported to have hypertension. The primary efficacy measures were mean change from baseline in the international index of erectile function (IIEF) erectile function (EF) domain and the proportion of 'yes' responses to sexual encounter profile (SEP) Questions 2 and 3. The tadalafil group showed a significantly (Po0.001) greater mean baseline to endpoint improvement on all efficacy outcome measures compared to placebo-treated patients regardless of concomitant thiazide use. More importantly, the responses to tadalafil were similar regardless of concomitant thiazide use. Additionally, responses to tadalafil were comparable between thiazide and nonthiazide users regardless of baseline ED severity (P40.05).
Introduction
The recently released 'Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7)' recommends thiazide-type diuretics to treat most patients with uncomplicated hypertension, either alone or in combination with drugs from other classes. 1 One reason for noncompliance with antihypertensives is the potential occurrence of side effects, which include sexual dysfunction. 2, 3 Hypertension itself is associated with erectile dysfunction (ED) and many antihypertensive medications cause ED, including beta-blockers and centrally acting agents; however, thiazide diuretics seem to be the most commonly implicated. In the Treatment of Mild Hypertension Study (TOMHS) and the Trial of Antihypertensive Interventions and Management (TAIM), the drug most commonly associated with ED was a thiazide diuretic, chlorthalidone. 4, 5 The mechanism for thiazide-induced ED has been hypothesized to be due to alterations in electrolytes, including the possibility of serum zinc deficiency, or volume depletion; 6 however, the exact mechanism remains to be determined.
Owing to the new recommendations for first-line treatment of hypertension with thiazide diuretics based on the JNC 7 report, recent results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 7 and a corresponding increase in the use of these agents, we examined whether tadalafil would demonstrate efficacy for the treatment of ED in men with hypertension receiving thiazide diuretics.
Methods

Study design
Data were analyzed from 14 randomized, doubleblind, placebo-controlled trials with a total of 2501 patients with ED. Of those patients, 163 were on concomitant thiazide-type diuretics (116 received tadalafil 20 mg and 47 placebo) and 159 of these 163 patients (97.5%) were reported to have hypertension. All studies involved 12 weeks of treatment, except for one, which lasted 26 weeks. For the purpose of the analyses presented here, only data gathered after 12 weeks of treatment are presented for the Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) questionnaire and the Sexual Encounter Profile (SEP) diary. Since the Global Assessment Question (GAQ) was not gathered at 12 weeks in the study lasting 26 weeks, the GAQ results reported are from 13 studies. The 14 studies included treatment arms with 2.5, 5, 10 and/or 20 mg tadalafil; however, only the 20 mg data are reported because the number of patients on the other doses and concomitant thiazides was too small for meaningful statistical analyses.
The study design of all 14 studies was similar: patients underwent a 4-week treatment-free run-in period followed by a 12-week treatment period in which tadalafil or placebo was taken as needed (a maximum of one dose per day) prior to sexual activity. Patients were asked to complete an SEP diary at the time of each sexual encounter and to complete the IIEF questionnaire at baseline after the treatment-free run-in period, and after 4, 8 and 12 weeks of treatment. All studies used the same three co-primary efficacy measures: mean change from baseline in the EF domain of the IIEF and the proportion of 'yes' responses to SEP Question 2 (SEP2: 'Were you able to insert your penis into your partner's vagina?' (yes/no)) and SEP Question 3 (SEP3: 'Did your erection last long enough for you to have successful intercourse?' (yes/no)). Additionally, the GAQ was asked at the end of the study 'Has the treatment you have been taking during this study improved your erections?' (yes/no).
Inclusion criteria and exclusion criteria were similar for all studies in this analysis. Inclusion criteria included men who were at least 18 y of age, who reported a minimum of 3 months history of ED and were to report on their sexual attempts with the same adult female partner. Exclusion criteria included unstable cardiovascular status (eg unstable angina, myocardial infarction or myocardial revascularization within the prior 90 days); a recent history of stroke or spinal cord trauma; use of nitrates, cancer chemotherapy or antiandrogens; failure to achieve any erection following radical prostatectomy or pelvic surgery; or clinically significant penile deformities or penile implants. All 14 of the studies excluded patients who, in the opinion of the investigator, were sildenafil nonresponders.
Patients were included in the thiazide diuretic group if they took any one of the following medications: bendroflumethiazide, benzylhydrochlorthiazide, chlorothiazide, chlorthalidone, hydrochlorothiazide, indapamide (a thiazide-like drug), metolazone or trichlormethiazide.
Patients with hypertension were identified by looking at the following diagnoses as defined by the Medical Dictionary for Regulatory Activities (Med-DRA: version 6.1, MedDRA Maintenance and Support Services Organization, Reston, Virginia, USA) on the case report form during the screening for the study using the data set of pre-existing conditions:
1. Vascular hypertensive disorders (high-level group term). 2. Blood pressure disorders NEC (high-level term). 3. Cardiac hypertensive complication (high-level term).
Of the four patients who were on thiazide diuretics but did not have a hypertension diagnosis, the diagnoses were: nephrolithiasis, renal colic, cardiac failure (congestive) and hyperlipidemia.
Statistical analysis
The analysis of efficacy was conducted on an intentto-treat basis. Analyses of covariance (ANCOVA) models were used to evaluate treatment differences for all continuous outcomes. Changes from baseline in IIEF EF domain, SEP2 and SEP3 were treated as continuous outcomes. The analysis included all patients who had a baseline measurement and at least one postbaseline measurement. The percentage of patients responding positively to GAQ was based on the number of patients who responded to that question. To test whether there is a difference in outcome measurement between treatment groups, an ANCOVA model was used by including terms such as treatment group, study, baseline and interaction between treatment group and baseline. To test whether there is a difference in outcome measurement between subgroups as defined by thiazide use, an ANCOVA model was used by including the term subgroup in addition to the terms stated previously. In any model, if the interaction was not significant (if PZ0.1), then it was removed from the model and the betweentreatment-group P-value was obtained from the reduced model. Furthermore, a subgroup-by-treatment-group-interaction term was added to test whether treatment effect was similar between subgroups. Logistic regression models were used to evaluate treatment differences for categorical variables (eg response to GAQ). The logistic regression model included covariate terms described previously in ANCOVA models. A subgroup analysis was conducted to test if treatment effect as measured by changes from baseline in IIEF EF, SEP2 and SEP3 was similar between thiazide users and nonusers in each level of baseline ED severity as defined by the Efficacy of tadalafil in men taking thiazides RA Kloner et al aggregated version of the Cappelleri categorization of IIEF EF domain of mild (17-25), moderate (11-16) and severe (1-10). 8 If patients reported a normal IIEF EF domain score (26-30) at baseline, they were included in the mild group for purposes of data analyses, since ED is a self-reported condition.
The analyses of safety in the 14 studies included all enrolled patients. Treatment-emergent adverse events (TEAEs)
Analyses were conducted using the SAS statistical package (SAS Institute, Cary, North Carolina, USA).
Results
Demographics and baseline characteristics
The baseline demographics of the patients not taking thiazides and taking thiazides are included in Table 1. A higher percentage of patients on thiazide therapy tended to have severe ED at baseline, as measured by the EF domain of the IIEF, as well as a longer ED history than those not on thiazides, even though none of these trends were statistically significant (P40.05). It is notable that a greater proportion of patients in the tadalafil-plus-thiazide group were older, were of African descent, and had comorbid conditions than those patients taking tadalafil and no thiazide.
Overall efficacy
Tadalafil improved EF for all coprimary outcomes when compared to placebo (IIEF EF, SEP2 and SEP 3), whether patients were taking or not taking thiazide diuretics (Table 2) . Results for GAQ are reported in Table 3 . Overall, the effect of tadalafil relative to placebo was similar for thiazide users and nonusers (P40.10).
Efficacy analysis stratified by baseline severity
Outcome measures were also examined based on ED severity scores at baseline. The efficacy analysis stratified by baseline ED severity consistently demonstrated that tadalafil effect relative to placebo, 
Adverse events
The tolerability of tadalafil was evaluated based on reports of TEAEs (Table 4) . No statistically significant difference was identified between thiazide users and nonusers in any of these events (P40.05), with the exception of upper respiratory tract infection (Po0.05 tadalafil/nonthiazide vs tadalafil/thiazide). Since the combination of tadalafil and an antihypertensive agent could potentially cause a lowering of blood pressure, terms indicating possible hypotension were compared: dizziness postural, syncope vasovagal, syncope, hypotension, orthostatic hypotension and loss of consciousness. There was no difference between the thiazide and nonthiazide groups in the incidence of these adverse events (P40.05).
Discussion
Placebo-controlled clinical trials have demonstrated the efficacy and safety of tadalafil for the treatment of ED. 9, 10 In this analysis, we examined whether tadalafil was as efficacious in patients taking concomitant thiazide diuretics for hypertension as in those not taking thiazides. Robust efficacy was demonstrated by tadalafil when compared to placebo as measured by change from baseline in IIEF EF score, SEP2 and SEP3 responses, and tadalafil was as effective in those patients taking thiazides as in those not taking thiazides. While thiazides are widely implicated in drug-related ED, there is little data available in analyzing efficacy of phosphodiesterase type 5 (PDE5) inhibitors in patients on Efficacy of tadalafil in men taking thiazides RA Kloner et al thiazides. Our data suggest that tadalafil was highly effective for the treatment of ED in men with hypertension on concomitant thiazide therapy. The importance of this finding is that thiazides are now considered to be the cornerstone of therapy for hypertension by many investigators. It is possible that tadalafil will improve compliance with thiazide diuretics in those men who are prone to develop ED with this kind of antihypertensive therapy. Our analysis also demonstrated that regardless of severity of ED, tadalafil was as effective in those patients taking thiazides as those not taking thiazides. Notably, there were trends for a higher percentage of those patients taking thiazides to have severe ED at baseline.
An important concern has been whether addition of PDE5 inhibitors to antihypertensive medicines will be associated with a worsening of adverse events of either compound, especially adverse events related to hypotension. Our analyses show that there was no difference in adverse events, except for upper respiratory tract infection, whether patients on tadalafil were taking thiazides or not. In particular, there was no increase in the incidence of hypotensive adverse events.
A limitation of this manuscript is that it is not known whether the ED in any of these patients was attributable to thiazides.
Conclusion
Thiazide diuretics have historically been implicated in causing or worsening ED. Since many men with ED have concomitant hypertension and require therapy such as thiazide diuretics, it is important to determine the efficacy of PDE5 inhibitors in the setting of thiazide diuretics. In examining the data from 14 studies, it is evident that tadalafil provides robust efficacy regardless of whether patients are taking thiazide diuretics. Tadalafil is demonstrated to be an effective option for those men with ED who are on concomitant thiazide therapy. Efficacy of tadalafil in men taking thiazides RA Kloner et al
